The Implant Metals Profile tests the circulating blood levels of the six metals that are most commonly associated with orthopedic and dental metal prostheses or implants. The metal debris may be associated with excessive physical wear or corrosion of the metal alloys. The greatest release of the metals occurs when prostheses entail metal-on-metal (M/M) bearing surfaces. Many studies have shown that the released metal debris may be associated with localized tissue damage to bone and soft tissue, sensitivity reactions, and remote adverse effects on normal physiological and biochemical functions. The reported blood metal levels should not be solely used to make conclusions regarding the integrity of metals prosthesis devices.
Learn more »
3 to 5 days
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
|Chromium, whole blood||82495||Yes|
|Cobalt, whole blood||83018||Yes|
|Molybdenum, whole blood||83018||Yes|
|Nickel, whole blood||83885||Yes|
|Titanium, whole blood||83018||Yes|
|Vanadium, whole blood||83018||Yes|
List price applies when filing with insurance or Medicare, or when billing a patient directly.
Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
The Implant Metals Panel is a blood test that measures the circulating levels of the six most commonly used metals for implants. The use of dental implants has helped preserve the integrity of jaw bones, and metal orthopedic implants have also improved the quality of life for many people. It has proven to be a daunting task to develop very durable and biocompatible materials for the devices, and the released metal debris may cause very localized as well as systemic adverse effects. Many patients suffer from the consequences of the released metal debris and the onset of symptoms can be “silent. “ Annual assessment of the levels of implant metals even in asymptomatic patients can be useful for preventive purposes.
The implant metals can be released by electrochemical corrosion, as is the case for titanium (TI) and Ti-alloys (nickel and vanadium), even when the Ti or Ti alloys are completely embedded in bone. Titanium has been long regarded as an inert biocompatible metal due to its corrosion resistance. However recent studies have shown that Ti and vanadium (V, minor component of Ti alloys) from non-bearing implant components can be released with potential consequential effects both locally and systemically. Ti may have adverse effects in blood, fibrotic tissues and osteogenic cells after transport through the circulatory or lymphatic systems. In a well-designed long-term animal model corrosion-released Ti increased blood Ti levels, and Ti concentrated primarily in the spleen and lungs to a lesser extent in the heart, kidneys and liver. There is a dearth of clinical data regarding potential adverse health effects of constant exposure and net retention of Ti. Vanadium is a minor constituent of titanium-aluminum-vanadium alloys used in some implants, and blood levels of V may be persistently higher than normal with Ti-alloy implants. In an extreme case markedly elevated blood V levels were associated with sensory-motor axonal neuropathy and bilateral sensorineural hearing loss. The patient did not have Ti alloy bearing surfaces but did suffer from a broken Ti alloy femoral stem. Nickel-containing Ti-alloys (about 50:50) have been used in the past primarily in dentistry. Much concern has been raised regarding the established cytotoxic, allergic and genotoxic activity of Ti-Ni alloys.
There is much greater release of metal debris from wear of metal-on-metal (M/M) orthopedic prostheses. Until very recently the majority total hip arthroplasty (THA) prostheses consisted of pairings of alloys of cobalt (Co), chromium (Cr), and molybdenum (Mo) for the acetabular cup and femoral head (Co:Cr:Mo about 60:30:7). The femoral head is attached to a femoral stem that is composed of Ti or Ti alloys. It is well established that the circulating levels of Co and Cr will be elevated indefinitely in all M/M THA patients. Further, Ti levels will also be elevated even when only the femoral stem is composed of pure Ti or a Ti alloy. A pattern of elevated blood Co, Cr and Ti is most common even in asymptomatic M/M THA patients. Local metallosis can cause pseudotumors (inflammatory soft tissue mass), decreased viability of osteoblastic bone marrow cells, osteoclastic bone resorption (release of lead), necrosis, and infiltration of macrophages, eosinophilic granulocytes and lymphocytes. The released metals may cause very significant damage to involved bone and soft tissue that too commonly causes misalignment and greater wear of the metal surfaces. Systemically elevated circulating and retained tissue levels of the metals, especially Co, can impair hepatic Phase I and II detoxification, induce excessive oxidative stress, compromise glutathione status and adversely affect redox potential. Signs and symptoms of arthtroprosthetic cobaltism include visual and auditory impairment, tinnitus, vertigo, cardiomyopathy, cognitive dysfunction /dementia, mood disorders, hypothyroidism, peripheral neuropathy and skin rashes. There are several case reports regarding neurotoxicity and cardiomyopathy associated with the disseminated metal debris, particularly Co. The American Academy of Orthopaedic Surgeons generally recommended assessment of circulating levels of Co and Cr for all M/M THA patients annually (asymptomatic), and every four-six months with mild symptoms.